参考文献

[1]叶仕高.内科学[M].6版.北京:人民卫生出版社, 2004: 663-666.

[2]Arruda V R, Schuettrumpf J, Herzog R W, et al.Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype I[J].Blood, 2004, 103(1): 85-92.

[3]Follenzi A, Battaglia M, Lombardo A, et al.Targeting lentiviral vector expression to hepatocytes limits transgenne-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice[J].Blood, 2004, 103(10): 3700-3701.

[4]Gilles J, Grailly S, Maeyer M, et al.In vivo neutralization of a C2 do main-specific human anti-Factor Ⅷ inhibitor by an anti-idiotypic antibody[J].Blood, 2004, 103(7): 2617-2623.

[5]Liu Shanxi, Jiang Lin, Liu Yiguo, et al.The effect and safety research on treatment of hemophilia with the Xueyou Mixture[J].Chin J Integr Med, 2007, 13(2):141-144.(https://www.daowen.com)

[6]Liu Shanxi, Jiang Lin, Liang Xin, et al.Study on classified curing hemophilic arthritis by integration traditional Chinese and Western medicine[J].Chin J Integr Med, 2007,13(4): 301-305.

[7]Ewenstein B M.Continuous infusion of recombinant factor Ⅶa: continue or not?[J].Thrmb Haemost, 2001, 86(4): 943-944.

[8]Aitken M G.Recombinant factor Ⅶa [J].Emerg Med Australas, 2004, 16(5-6): 446.

[9]Bishop P, Lawson J.Recombinant biologic for treatment of bleeding disorder [J].Nature, 2004,8(3):684.

[10]徐世渊, 肖小璞.重组活化的凝血因子Ⅶ与肝脏疾病治疗中的应用[J].中国输血杂志,2006, 19(2):152-153.